Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitters ...

An update from ImmunityBio ( (IBRX)) is now available. On December 10, 2025, ImmunityBio, Inc. appointed Bruce Wendel to its Board of Directors, effective December 12, 2025, with his term expiring at ...

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on ...

ImmunityBio Inc. (NASDAQ:IBRX) is among the best US stocks to buy under $20. As of November 26, ImmunityBio Inc. (NASDAQ:IBRX) is a consensus Buy, with all analysts covering it assigning a Buy or ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Tuesday reported a loss of $67.3 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 7 ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

Despite hopes for a production facility for ImmunityBio, the town of Dunkirk plant off Route 5 is an empty ghost town. Standing in front of the Tesla Gigafactory in South Buffalo in the middle of July ...

Anktiva, the bladder cancer drug platform by Culver City-based ImmunityBio, lands approval by the United Kingdom’s drug regulatory agency. Research: An ImmunityBio facility in El Segundo. (Photo by ...